Trop-2 Targeted PET Probes in Advanced TNBC

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

September 1, 2027

Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
DRUG

Sacituzumab Govitecan (SG)

After enrollment, before subjects receive TROP-2 ADC treatment, after 2 cycles of treatment, and at the time of progression, in these three phases, subjects will undergo 89Zr-DFO-hSR7 and 18F-FDG examinations once respectively (subjects will first undergo the 18F-FDG examination, and then the 89Zr-DFO-hSR7 examination within 1 week).

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER